Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $40.12, for a total transaction of $1,003,000.00. Following the transaction, the chief executive officer directly owned 1,516,667 shares in the company, valued at approximately $60,848,680.04. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Liquidia Price Performance

Liquidia stock opened at $38.85 on Tuesday. The firm has a fifty day moving average of $36.87 and a 200-day moving average of $32.92. Liquidia Corporation has a 52-week low of $11.85 and a 52-week high of $46.67. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $3.42 billion, a P/E ratio of -46.81 and a beta of 0.45.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. The business’s revenue was up 3072.4% compared to the same quarter last year. As a group, analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia during the fourth quarter worth approximately $25,000. NewEdge Advisors LLC bought a new position in Liquidia during the 2nd quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Liquidia during the 3rd quarter worth $30,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia in the 3rd quarter worth about $34,000. Finally, Covestor Ltd raised its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC increased their target price on Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Oppenheimer raised their price target on shares of Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a report on Thursday, March 12th. Finally, HC Wainwright boosted their price objective on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and an average price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).